• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

研磨辅助药物载入介孔二氧化硅载体：一种获得可调控定制药物递送的绿色简便方法。

Milling-Assisted Loading of Drugs into Mesoporous Silica Carriers: A Green and Simple Method for Obtaining Tunable Customized Drug Delivery.

作者信息

Moutamenni Basma, Tabary Nicolas, Mussi Alexandre, Dhainaut Jeremy, Ciotonea Carmen, Fadel Alexandre, Paccou Laurent, Dacquin Jean-Philippe, Guinet Yannick, Hédoux Alain

机构信息

UMR 8207, UMET-Unité Matériaux et Transformations, University Lille, CNRS, INRAE, Centrale Lille, F-59000 Lille, France.

UMR 8181, UCCS-Unité de Catalyse et Chimie du Solide, University Lille, CNRS, Centrale Lille, University Artois, F-59000 Lille, France.

出版信息

Pharmaceutics. 2023 Jan 24;15(2):390. doi: 10.3390/pharmaceutics15020390.

DOI:10.3390/pharmaceutics15020390
PMID:36839712
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9968001/
Abstract

Mesoporous silica (MPS) carriers are considered as a promising strategy to increase the solubility of poorly soluble drugs and to stabilize the amorphous drug delivery system. The development by the authors of a solvent-free method (milling-assisted loading, MAL) made it possible to manipulate the physical state of the drug within the pores. The present study focuses on the effects of the milling intensity and the pore architecture (chemical surface) on the physical state of the confined drug and its release profile. Ibuprofen (IBP) and SBA-15 were used as the model drug and the MPS carrier, respectively. It was found that decreasing the milling intensity promotes nanocrystallization of confined IBP. Scanning electron microscopy and low-frequency Raman spectroscopy investigations converged into a bimodal description of the size distribution of particles, by decreasing the milling intensity. The chemical modification of the pore surface with 3-aminopropyltriethoxisylane also significantly promoted nanocrystallization, regardless of the milling intensity. Combined analyses of drug release profiles obtained on composites prepared from unmodified and modified SBA-15 with various milling intensities showed that the particle size of composites has the greatest influence on the drug release profile. Tuning drug concentration, milling intensity, and chemical surface make it possible to easily customize drug delivery.

摘要

介孔二氧化硅（MPS）载体被认为是一种提高难溶性药物溶解度和稳定无定形药物递送系统的有前景的策略。作者开发的无溶剂方法（研磨辅助负载，MAL）使得在孔内操纵药物的物理状态成为可能。本研究聚焦于研磨强度和孔结构（化学表面）对受限药物物理状态及其释放曲线的影响。分别使用布洛芬（IBP）和SBA-15作为模型药物和MPS载体。发现降低研磨强度会促进受限IBP的纳米结晶。通过降低研磨强度，扫描电子显微镜和低频拉曼光谱研究得出了颗粒尺寸分布的双峰描述。用3-氨丙基三乙氧基硅烷对孔表面进行化学改性也显著促进了纳米结晶，而与研磨强度无关。对由不同研磨强度的未改性和改性SBA-15制备的复合材料获得的药物释放曲线进行的综合分析表明，复合材料的粒径对药物释放曲线影响最大。调节药物浓度、研磨强度和化学表面使得轻松定制药物递送成为可能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/cffd7b632346/pharmaceutics-15-00390-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/f7bfbff0b1af/pharmaceutics-15-00390-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/f1b4998aa57e/pharmaceutics-15-00390-g0A2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/974a64cf7955/pharmaceutics-15-00390-g0A3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/d83d9fe4eb1e/pharmaceutics-15-00390-g0A4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/71eaf21a97ff/pharmaceutics-15-00390-g0A5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/cf7ff53698b8/pharmaceutics-15-00390-g0A6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/ad094ecf1b5f/pharmaceutics-15-00390-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/4cd79880c31a/pharmaceutics-15-00390-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/4cc61590e97a/pharmaceutics-15-00390-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/8f098582d644/pharmaceutics-15-00390-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/0665e18809e8/pharmaceutics-15-00390-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/b93c5d3e80ec/pharmaceutics-15-00390-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/d2b3d85a0c5a/pharmaceutics-15-00390-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/141feeef981f/pharmaceutics-15-00390-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/a5af25e25b70/pharmaceutics-15-00390-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/cffd7b632346/pharmaceutics-15-00390-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/f7bfbff0b1af/pharmaceutics-15-00390-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/f1b4998aa57e/pharmaceutics-15-00390-g0A2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/974a64cf7955/pharmaceutics-15-00390-g0A3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/d83d9fe4eb1e/pharmaceutics-15-00390-g0A4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/71eaf21a97ff/pharmaceutics-15-00390-g0A5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/cf7ff53698b8/pharmaceutics-15-00390-g0A6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/ad094ecf1b5f/pharmaceutics-15-00390-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/4cd79880c31a/pharmaceutics-15-00390-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/4cc61590e97a/pharmaceutics-15-00390-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/8f098582d644/pharmaceutics-15-00390-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/0665e18809e8/pharmaceutics-15-00390-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/b93c5d3e80ec/pharmaceutics-15-00390-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/d2b3d85a0c5a/pharmaceutics-15-00390-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/141feeef981f/pharmaceutics-15-00390-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/a5af25e25b70/pharmaceutics-15-00390-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5295/9968001/cffd7b632346/pharmaceutics-15-00390-g010.jpg

相似文献

1
Milling-Assisted Loading of Drugs into Mesoporous Silica Carriers: A Green and Simple Method for Obtaining Tunable Customized Drug Delivery.研磨辅助药物载入介孔二氧化硅载体：一种获得可调控定制药物递送的绿色简便方法。
Pharmaceutics. 2023 Jan 24;15(2):390. doi: 10.3390/pharmaceutics15020390.
2
Manipulating the physical states of confined ibuprofen in SBA-15 based drug delivery systems obtained by solid-state loading: Impact of the loading degree.通过固态负载法获得的 SBA-15 载药体系中布洛芬的物理状态调控：负载程度的影响。
J Chem Phys. 2020 Oct 21;153(15):154506. doi: 10.1063/5.0020992.
3
A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.基于超临界流体技术设计缓控释难溶性药物介孔硅微球的新策略。
Int J Pharm. 2013 Sep 15;454(1):135-42. doi: 10.1016/j.ijpharm.2013.07.027. Epub 2013 Jul 17.
4
Modifying release of poorly soluble active pharmaceutical ingredients with the amine functionalized SBA-16 type mesoporous materials.用胺功能化 SBA-16 型介孔材料修饰难溶性活性药物成分的释放。
J Biomater Appl. 2019 Apr;33(9):1214-1231. doi: 10.1177/0885328219830823. Epub 2019 Feb 21.
5
How Molecular Mobility, Physical State, and Drug Distribution Influence the Naproxen Release Profile from Different Mesoporous Silica Matrices.分子迁移率、物理状态和药物分布如何影响不同介孔硅基质中萘普生的释放特性。
Mol Pharm. 2021 Mar 1;18(3):898-914. doi: 10.1021/acs.molpharmaceut.0c00908. Epub 2021 Jan 18.
6
Amorphization and modified release of ibuprofen by post-synthetic and solvent-free loading into tailored silica aerogels.通过后合成和无溶剂负载到定制的硅气凝胶中来实现布洛芬的无定形化和改良释放。
Drug Deliv. 2022 Dec;29(1):2086-2099. doi: 10.1080/10717544.2022.2092237.
7
Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: influence of pore size on release rate.利用三维面心立方介孔二氧化硅作为难溶性药物的载体：孔径对释放速率的影响。
Mater Sci Eng C Mater Biol Appl. 2014 Jan 1;34:78-85. doi: 10.1016/j.msec.2013.08.014. Epub 2013 Aug 17.
8
Ordered nanoporous silica as carriers for improved delivery of water insoluble drugs: a comparative study between three dimensional and two dimensional macroporous silica.有序纳米孔硅作为载体提高难溶性药物的递送：三维和二维大孔硅的比较研究。
Int J Nanomedicine. 2013;8:4015-31. doi: 10.2147/IJN.S52605. Epub 2013 Oct 22.
9
Ketoprofen mesoporous silica nanoparticles SBA-15 hard gelatin capsules: preparation and in vitro/in vivo characterization.酮洛芬介孔二氧化硅纳米粒子SBA - 15硬明胶胶囊：制备及体外/体内表征
Drug Deliv. 2016 Nov;23(9):3387-3398. doi: 10.1080/10717544.2016.1186251. Epub 2016 Jun 3.
10
Improved solubility of lornoxicam by inclusion into SBA-15: Comparison of loading methods.洛索洛芬包载入 SBA-15 后溶解度提高：负载方法比较。
Eur J Pharm Sci. 2022 Apr 1;171:106133. doi: 10.1016/j.ejps.2022.106133. Epub 2022 Jan 21.

本文引用的文献

1
Confinement of molecular materials using a solid-state loading method: a route for exploring new physical states and their subsequent transformation highlighted by caffeine confined to SBA-15 pores.使用固态负载方法限制分子材料：一条探索新物理状态及其后续转变的途径，以咖啡因限制在SBA - 15孔中为例进行说明。
RSC Adv. 2021 Oct 26;11(55):34564-34571. doi: 10.1039/d1ra05757j. eCollection 2021 Oct 25.
2
Mesoporous Silica Particles as Drug Delivery Systems-The State of the Art in Loading Methods and the Recent Progress in Analytical Techniques for Monitoring These Processes.介孔二氧化硅颗粒作为药物递送系统——负载方法的现状及监测这些过程的分析技术的最新进展
Pharmaceutics. 2021 Jun 24;13(7):950. doi: 10.3390/pharmaceutics13070950.
3
Manipulating the physical states of confined ibuprofen in SBA-15 based drug delivery systems obtained by solid-state loading: Impact of the loading degree.
通过固态负载法获得的 SBA-15 载药体系中布洛芬的物理状态调控：负载程度的影响。
J Chem Phys. 2020 Oct 21;153(15):154506. doi: 10.1063/5.0020992.
4
Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights.介孔二氧化硅纳米颗粒用于药物传递：当前的见解。
Molecules. 2017 Dec 25;23(1):47. doi: 10.3390/molecules23010047.
5
Comparison of amorphous states prepared by melt-quenching and cryomilling polymorphs of carbamazepine.通过熔融淬火和冷冻研磨制备的卡马西平多晶型物的非晶态比较。
Int J Pharm. 2016 Jul 25;509(1-2):305-313. doi: 10.1016/j.ijpharm.2016.05.050. Epub 2016 May 27.
6
Recent advances in co-amorphous drug formulations.共无定形药物制剂的最新进展。
Adv Drug Deliv Rev. 2016 May 1;100:116-25. doi: 10.1016/j.addr.2015.12.009. Epub 2016 Jan 21.
7
Recent developments in the Raman and infrared investigations of amorphous pharmaceuticals and protein formulations: A review.最近在拉曼和红外研究非晶态药物和蛋白质配方方面的进展：综述。
Adv Drug Deliv Rev. 2016 May 1;100:133-46. doi: 10.1016/j.addr.2015.11.021. Epub 2015 Dec 10.
8
Comparison of fenofibrate-mesoporous silica drug-loading processes for enhanced drug delivery.比较载有非诺贝特的介孔硅药物加载工艺，以增强药物传递。
Eur J Pharm Sci. 2013 Nov 20;50(3-4):400-9. doi: 10.1016/j.ejps.2013.08.026. Epub 2013 Aug 24.
9
Polymorphic transformation of anhydrous caffeine upon grinding and hydrostatic pressurizing analyzed by low-frequency raman spectroscopy.采用低频拉曼光谱分析研磨和静水压加压对无水咖啡因的多晶型转变的影响。
J Pharm Sci. 2013 Jan;102(1):162-70. doi: 10.1002/jps.23346. Epub 2012 Oct 25.
10
The contribution of Raman spectroscopy to the analysis of phase transformations in pharmaceutical compounds.拉曼光谱在药物化合物相变分析中的贡献。
Int J Pharm. 2011 Sep 30;417(1-2):17-31. doi: 10.1016/j.ijpharm.2011.01.031. Epub 2011 Jan 21.